Rapid clearance of antigen complexes using novel antibodies
AssigneeXencor, Inc.
InventorsGregory L. Moore, John Desjarlais, Matthew Bernett
Life of this patent
Estimating the term…
Abstract
The present invention relates to rapid clearance molecules that bind target antigens and FcγRIIb with increased affinity as compared to parent molecules, said compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety of other conditions.
Claims11
1-22. (canceled)
A method of treating an autoimmune disorder in a patient by rapidly lowering serum concentration of C3d in said patient, said method comprising:
- a) administering a rapid clearance molecule comprising:
- i) a variable region that binds said C3d;
- and
- a variant Fc domain comprising an amino acid substitution as compared to a parent Fc domain, wherein said variant Fe domain binds FcγRIIb with increased affinity as compared to said parent Fc domain;
- wherein said rapid clearance molecule binds to said C3d to form an molecule-C3d complex and said complex is cleared at least two fold faster than C3d alone.
A method of treating atherosclerosis in a patient by rapidly lowering serum concentration of oxLDL in said patient, said method comprising:
- a) administering a rapid clearance molecule comprising:
- i) a variable region that binds said oxLDL;
- and
- ii) a variant Fc domain comprising an amino acid substitution as compared to a parent Fc domain, wherein said variant Fc domain binds FcγRIIb with increased affinity as compared to said parent Fc domain;
- wherein said rapid clearance molecule binds to said oxLDL to form a molecule-oxLDL complex and said complex is cleared at least two fold faster than oxLDL alone.
30-32. (canceled)
Dependencies are inferred from the claim text.